Regeneron Pharmaceuticals (REGN) Could Be 7% Undervalued After Libtayo And Pasatru Updates

Regeneron Pharmaceuticals (REGN) is back in focus after two product updates in October. Fresh CHMP backing for a less frequent Libtayo dosing schedule and extended Pasatru data give investors new angles to assess the stock.

Against that backdrop, Regeneron Pharmaceuticals has seen momentum build over the past quarter, with a 90 day share price return of 17.64% and a 1 year total shareholder return of 37.50%, even though the 3 year total shareholder return is slightly in decline at 1.27%.

Scan how Regeneron Pharmaceuticals compares to other drug developers by lining it up against 33 healthcare AI stocks that are harnessing data and biology to build the next wave of treatment breakthroughs.

Bulls see fresh Libtayo flexibility and rare disease traction as fuel for Regeneron Pharmaceuticals, while bears point to an already strong share run. Which story will the current valuation reflect next?

Most Popular Narrative: 7% Undervalued

The most followed narrative pegs Regeneron Pharmaceuticals at a fair value of about $850.88 using a 7.55% discount rate, compared with a last close of $790.74. This frames the recent rally as only part of the story.

Regeneron Pharmaceuticals is still advancing a broad late stage pipeline in areas such as immunology, oncology, genetic medicines, and obesity. Continued readouts and regulatory decisions on these programs can add new revenue streams that support earnings growth beyond the current product portfolio.

See why 86 investors see Regeneron Pharmaceuticals as 7% undervalued.

Result: Fair Value of $850.88 (UNDERVALUED)

Still, this bullish Regeneron Pharmaceuticals story can unravel if Kodiak Sciences’ Zenkuda reshapes the retinal market or Libtayo related lawsuits weigh on sentiment and valuation multiples.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Next Steps

If this Regeneron Pharmaceuticals story feels tilted in one direction, pressure test it by running your own numbers and weighing the signals yourself. To see a concise summary of what investors currently view as the upside, start with the 2 key rewards.

Looking for more investment ideas beyond Regeneron Pharmaceuticals?

Do not stop at Regeneron Pharmaceuticals if you want a fuller watchlist. Use the Simply Wall Street Screener to pull in fresh, data driven ideas that match your style.

• Target stronger balance sheets by scanning a list of solid balance sheet and fundamentals (25 results). This can help anchor a portfolio when sentiment swings.
• Hunt for mispriced quality with a 33 high quality undervalued stocks that filters for fundamentals first so you can focus on businesses rather than hype.
• Spot early stage potential through a 14 elite penny stocks with strong financials filtered for financial strength before headlines start chasing them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com